Get the Stockscreener App
5.785
3.24%
-0.225
Savara Inc stock is traded at $5.785, with a volume of 456.81K.
It is down -3.24% in the last 24 hours and up +2.74% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$6.01
Open:
$6
24h Volume:
456.81K
Relative Volume:
0.20
Market Cap:
$1.18B
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-17.53
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+3.10%
1M Performance:
+2.74%
6M Performance:
+70.03%
1Y Performance:
+150.65%
1-Day Range:
$5.70
$6.01
1-Week Range:
$5.61
$6.145
52-Week Range:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.785 | 1.22B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.04 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.32 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.08 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.98 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.69 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MyChesCo
Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application - simplywall.st
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears - Yahoo Finance
Savara, Inc. (SVRA) Investor Outlook: An 81% Upside Potential In Rare Respiratory Disease Treatment - DirectorsTalk Interviews
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Citizens reiterates Savara stock rating on likely FDA approval - Investing.com Nigeria
Is FDA Priority Review for MOLBREEVI Reshaping the Investment Case for Savara (SVRA)? - simplywall.st
Savara Grants Inducement Equity Awards to New Employee - MyChesCo
Citizens reiterates Savara stock rating on likely FDA approval By Investing.com - Investing.com India
Savara, Inc. (SVRA) Stock Analysis: Biotech Player With An 89% Upside Potential - DirectorsTalk Interviews
Savara (SVRA) Gains Priority Review for Molbreevi by FDA - GuruFocus
FDA accepts Savara’s drug application for rare lung disease - Investing.com India
Savara's Molbreevi BLA for Autoimmune Pulmonary Alveolar Proteinosis Accepted for FDA Review - marketscreener.com
Savara (SVRA) Gains FDA Priority Review for Molbreevi BLA - GuruFocus
FDA Grants Priority Review to Savara's (SVRA) Molbreevi BLA - GuruFocus
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - The AI Journal
FDA accepts Savara’s drug application for rare lung disease By Investing.com - Investing.com UK
Chart Watch: Whats the fair value of Savara Inc stockStop Loss & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach - TipRanks
GSA Capital Partners LLP Has $1.33 Million Stock Holdings in Savara Inc. $SVRA - MarketBeat
Major Savara Inc. (SVRA) holder reports 6.1% stake in Schedule 13G/A - Stock Titan
Savara (SVRA) Is Up 7.1% After BLA Resubmission And Pricing Reveal For Lead aPAP TherapyHas The Bull Case Changed? - simplywall.st
Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit - MarketBeat
Risk Check: Whats the fair value of Savara Inc stockQuarterly Earnings Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
What dividend safety score for Savara Inc. stockEarnings Growth Report & Safe Entry Point Identification - mfd.ru
SVRA Should I Buy - Intellectia AI
Savara Announces New Employment Inducement Grant - The Joplin Globe
Savara (NASDAQ:SVRA) Shares Up 6.8%Here's Why - MarketBeat
Should I set a stop loss on Savara Inc.Dividend Hike & Stepwise Entry/Exit Trade Alerts - mfd.ru
Growth Value: Is Savara Inc being accumulated by smart moneyEarnings Trend Report & Verified Trade Idea Suggestions - baoquankhu1.vn
Savara Insiders Added US$535.6k Of Stock To Their Holdings - Yahoo Finance
Savara Secures Path to $150M as FDA Decision Nears for Rare Lung Drug - MyChesCo
Savara Announces Participation in Upcoming February 2026 Investor Healthcare Conferences - BioSpace
Savara Inc. (NASDAQ:SVRA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara (NASDAQ:SVRA) Trading 2.5% HigherShould You Buy? - MarketBeat
Expanded Hercules Credit Line Tied To MOLBREEVI Approval Could Be A Game Changer For Savara (SVRA) - simplywall.st
ETF Watch: Why is Savara Inc stock going downQuarterly Performance Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Savara grants equity awards to new hires as it advances rare lung drug - MSN
Growth Report: Is Savara Inc being accumulated by smart moneyQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Movement Recap: Will Savara Inc announce a stock splitStock Surge & AI Enhanced Execution Alerts - baoquankhu1.vn
Savara, Inc. (SVRA) Investor Outlook: Analyst Ratings Signal A Potential 93.77% Upside - DirectorsTalk Interviews
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI - BioSpace
Savara secures additional $75m in debt financing for potential drug launch - Investing.com Australia
Hercules Capital Ties Savara Funding To FDA Milestone And Valuation Case - simplywall.st
A Look At Hercules Capital (HTGC) Valuation After The Expanded Savara Loan Agreement - Yahoo Finance
Savara Reports Amendment to Hercules Capital Debt Facility - marketscreener.com
Savara amends loan agreement to access up to $105 million in term loans - Investing.com Nigeria
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - MyChesCo
How Investors May Respond To Savara (SVRA) Adding Approval-Linked Hercules Credit To Its Liquidity Toolkit - simplywall.st
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):